# Performance characteristics and potential public health impact of improved pre-erythrocytic malaria vaccines targeting childhood burden

**Josephine Malinga<sup>1,2</sup>, Lydia Braunack-Mayer<sup>3,4</sup>, Thiery Masserey<sup>3,4</sup>, Matthew Cairns<sup>3</sup> , Sherrie L Kelly<sup>1,2</sup>, Epke Le Rutte<sup>1</sup>, Narimane Nekkab<sup>3,4</sup>, Melissa A Penny<sup>1,2,3,4</sup>**

_<sup>1</sup> The Kids Research Institute, Nedlands, WA, Australia; <sup>2</sup> Centre for Child Health Research, University of Western Australia, Crawley, WA, Australia; <sup>3</sup>Swiss Tropical and Public Health Institute, Allschwil, Switzerland; <sup>4</sup>University of Basel, Basel, Switzerland; <sup>5</sup>London School of Hygiene and Tropical Medicine, London, United Kingdom_ 

*Correspondence to: melissa.penny@thekids.org.au

Using an individual-based malaria transmission model (https://github.com/SwissTPH/openmalaria/wiki) we evaluate the population level impact of deploying a long duration pre-erythrocytic vaccine, linking vaccine performance properties, health system and programmatic factors and understanding their trade-offs and relationships.
